PLA2G4B anticorps (AA 514-781)

N° du produit ABIN7149404

Cet anticorps Lapin Polyclonal détecte spécifiquement PLA2G4B dans WB, ELISA, IHC et IF. Il présente une réactivité envers Humain.

Aperçu rapide pour PLA2G4B anticorps (AA 514-781) (ABIN7149404)

Antigène: PLA2G4B (Phospholipase A2, Group IVB (Cytosolic) (PLA2G4B))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PLA2G4B est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Détail du produit anti-PLA2G4B anticorps

Épitope: AA 514-781

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Cytosolic phospholipase A2 beta protein (514-781AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:1000-1:5000, IHC:1:200-1:500, IF:1:50-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur PLA2G4B

Antigène: PLA2G4B (Phospholipase A2, Group IVB (Cytosolic) (PLA2G4B))

Autre désignation: PLA2G4B

Sujet:

Background: Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position with a preference for arachidonoyl phospholipids. Has a much weaker activity than PLA2G4A. Isoform 3 has calcium-dependent activity against palmitoyl-arachidonyl-phosphatidylethanolamine and low level lysophospholipase activity but no activity against phosphatidylcholine. Isoform 5 does have activity against phosphatidylcholine.

Aliases: PLA2G4B antibody, Cytosolic phospholipase A2 beta antibody, cPLA2-beta antibody, EC 3.1.1.4 antibody, Phospholipase A2 group IVB antibody

UniProt: P0C869

Pathways: ER-Nucleus Signaling, VEGF Signaling